[go: up one dir, main page]

WO2008004992A3 - Formulations transdermiques contenant des immunogènes du virus de hépatite c - Google Patents

Formulations transdermiques contenant des immunogènes du virus de hépatite c Download PDF

Info

Publication number
WO2008004992A3
WO2008004992A3 PCT/US2006/020101 US2006020101W WO2008004992A3 WO 2008004992 A3 WO2008004992 A3 WO 2008004992A3 US 2006020101 W US2006020101 W US 2006020101W WO 2008004992 A3 WO2008004992 A3 WO 2008004992A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations containing
transdermal delivery
transdermal formulations
ethoxylated oil
containing hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/020101
Other languages
English (en)
Other versions
WO2008004992A2 (fr
Inventor
Frederick Jordan
Matti Sallberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tripep AB
ORYXE
Original Assignee
Tripep AB
ORYXE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tripep AB, ORYXE filed Critical Tripep AB
Anticipated expiration legal-status Critical
Publication of WO2008004992A2 publication Critical patent/WO2008004992A2/fr
Publication of WO2008004992A3 publication Critical patent/WO2008004992A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Les modes de réalisation selon la présente invention concernent la découverte de plusieurs formulations d'une composition de diffusion transdermique permettant d'administrer des composés de masses moléculaires faibles et élevées, de préférence des antigènes et des immunogènes du virus de l'hépatite C (HCV), à un sujet. L'invention concerne lesdites compositions de diffusion transdermique, des dispositifs de diffusion transdermique permettant d'administrer lesdites compositions à des sujets nécessitant des soins, et des procédés de fabrication et d'utilisation desdites compositions et dispositifs.
PCT/US2006/020101 2005-05-25 2006-05-24 Formulations transdermiques contenant des immunogènes du virus de hépatite c Ceased WO2008004992A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68503505P 2005-05-25 2005-05-25
US60/685,035 2005-05-25

Publications (2)

Publication Number Publication Date
WO2008004992A2 WO2008004992A2 (fr) 2008-01-10
WO2008004992A3 true WO2008004992A3 (fr) 2009-01-29

Family

ID=38895039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/020101 Ceased WO2008004992A2 (fr) 2005-05-25 2006-05-24 Formulations transdermiques contenant des immunogènes du virus de hépatite c

Country Status (1)

Country Link
WO (1) WO2008004992A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10076491B2 (en) * 2013-02-05 2018-09-18 Nitto Denko Corporation Vaccine composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013855A2 (fr) * 2000-08-17 2002-02-21 Tripep Ab Vaccins contenant de la ribavirine et procedes d'utilisation associes
WO2004048402A2 (fr) * 2002-11-26 2004-06-10 Tripep Ab Gene de fusion ns3/4a non structurel a codons optimises du virus de l'hepatite c
WO2005039464A1 (fr) * 2003-10-10 2005-05-06 Oryxe Composes transdermiques a poids moleculaires faible et eleve

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013855A2 (fr) * 2000-08-17 2002-02-21 Tripep Ab Vaccins contenant de la ribavirine et procedes d'utilisation associes
WO2004048402A2 (fr) * 2002-11-26 2004-06-10 Tripep Ab Gene de fusion ns3/4a non structurel a codons optimises du virus de l'hepatite c
WO2005039464A1 (fr) * 2003-10-10 2005-05-06 Oryxe Composes transdermiques a poids moleculaires faible et eleve

Also Published As

Publication number Publication date
WO2008004992A2 (fr) 2008-01-10

Similar Documents

Publication Publication Date Title
WO2008014979A3 (fr) Acide nucléique de formule (i): gixmgn, ou(ii): cixmcn, en particulier en tant qu'agent/adjuvant immunostimulant
WO2008021936A3 (fr) Inhibiteurs du virus de l'hépatite c
WO2004087153A3 (fr) Utilisation de petites molecules de composes pour une immunopotentialisation
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
ZA200900935B (en) Hepatitis C virus inhibitors
WO2007052155A3 (fr) Vaccins antigrippaux presentant un taux reduit d'adjuvants de type emulsion
WO2008021927A3 (fr) Inhibiteurs du virus de l'hépatite c
DK2468300T3 (da) Vaccinesammensætning indeholdende syntetisk adjuvant
EA201001276A1 (ru) Ингибиторы вируса гепатита с
WO2007052058A8 (fr) Vaccins influenza comprenant des combinaisons d'adjuvants particulaires et d'immunopotentiateurs
WO2008039267A3 (fr) Induction de réponses immunes cellulaires au virus de la grippe grâce à des compositions de peptides et d'acides nucléiques
WO2009143457A3 (fr) Composition de vaccin contenant un adjuvant synthétique
UA88909C2 (ru) Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с, фармацевтическая композиция на их основе и их применение
EP2589602A3 (fr) Développement de composants de vaccins du virus de la dengue
AR061894A1 (es) Vacunas para malaria
DK1898948T3 (da) Polyriboinosinsyre-polyribocytidylsyre-baseret adjuvans
CU23759A3 (es) Composiciones inmunogénicas
AU2003246373A8 (en) Recombinant measles viruses expressing epitopes of antigens of rna viruses - use for the preparation of vaccine compositions
MA32821B1 (fr) Vaccin combine notamment contre la coqueluche (vaccin cellulaire entier)
SG160336A1 (en) Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
WO2009080715A3 (fr) Vaccins anti-malaria
WO2006138568A3 (fr) Immunotherapie multivalente a effet de declenchement et d'amplification, destinee au traitement d'une tumeur cancereuse
WO2006074303A3 (fr) Vehicules d'administration, substances bioactives et vaccins viraux
WO2005107796A3 (fr) Facteur de permissivite cellulaire pour virus, et son utilisation
WO2008008541A8 (fr) Procédés destinés à susciter, améliorer et entretenir les réponses immunitaires contre des épitopes limités au cmh de classe i dans des buts prophylactiques ou thérapeutiques

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06851396

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06851396

Country of ref document: EP

Kind code of ref document: A2